| 1 |
35584371 | Severe Hyponatremia During First Cycle of Cyclophosphamide/Doxorubicin Chemotherapy. | 2022 May 18 |
1 |
| 2 |
33136364 | Matrix Stiffness-Regulated Growth of Breast Tumor Spheroids and Their Response to Chemotherapy. | 2021 Feb 8 |
1 |
| 3 |
33614637 | Estrogen Receptor α Mediates Doxorubicin Sensitivity in Breast Cancer Cells by Regulating E-Cadherin. | 2021 |
12 |
| 4 |
33867840 | MnSOD Lysine 68 acetylation leads to cisplatin and doxorubicin resistance due to aberrant mitochondrial metabolism. | 2021 |
2 |
| 5 |
34681897 | Suppression of Estrogen Receptor Alpha Inhibits Cell Proliferation, Differentiation and Enhances the Chemosensitivity of P53-Positive U2OS Osteosarcoma Cell. | 2021 Oct 18 |
2 |
| 6 |
34722965 | Targeting Estrogen Receptor-Positive Breast Microtumors with Endoxifen-Conjugated, Hypoxia-Sensitive Polymersomes. | 2021 Oct 26 |
2 |
| 7 |
31883395 | Modeling Neoadjuvant chemotherapy resistance in vitro increased NRP-1 and HER2 expression and converted MCF7 breast cancer subtype. | 2020 May |
1 |
| 8 |
32269999 | A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy. | 2020 |
3 |
| 9 |
32742395 | Elevated estrogen receptor β expression in triple negative breast cancer cells is associated with sensitivity to doxorubicin by inhibiting the PI3K/AKT/mTOR signaling pathway. | 2020 Aug |
4 |
| 10 |
32926627 | Hypoxia-Responsive, Polymeric Nanocarriers for Targeted Drug Delivery to Estrogen Receptor-Positive Breast Cancer Cell Spheroids. | 2020 Nov 2 |
1 |
| 11 |
33204396 | Cellular Mechanisms Triggered by the Cotreatment of Resveratrol and Doxorubicin in Breast Cancer: A Translational In Vitro-In Silico Model. | 2020 |
1 |
| 12 |
33299647 | Role of chromosomal instability and clonal heterogeneity in the therapy response of breast cancer cell lines. | 2020 Nov 15 |
1 |
| 13 |
31645610 | Regulatory Crosstalk of Doxorubicin, Estradiol and TNFα Combined Treatment in Breast Cancer-derived Cell Lines. | 2019 Oct 23 |
1 |
| 14 |
29644867 | Ultrasonically controlled estrone-modified liposomes for estrogen-positive breast cancer therapy. | 2018 |
2 |
| 15 |
29779937 | Estrogen receptor positive breast tumors resist chemotherapy by the overexpression of P53 in Cancer Stem Cells. | 2018 Jun |
1 |
| 16 |
29937544 | Interaction of WBP2 with ERα increases doxorubicin resistance of breast cancer cells by modulating MDR1 transcription. | 2018 May 1 |
1 |
| 17 |
33168517 | [Effect of gap junction modulation on antitumor effects of adriamycin in estrogen receptor-positive breast cancer cells]. | 2018 Jul 30 |
4 |
| 18 |
28000875 | Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression. | 2017 Feb |
1 |
| 19 |
28223545 | Ring finger protein 6 promotes breast cancer cell proliferation by stabilizing estrogen receptor alpha. | 2017 Mar 21 |
1 |
| 20 |
28455002 | Treatment schedule and estrogen receptor-status influence acquisition of doxorubicin resistance in breast cancer cells. | 2017 Jun 15 |
4 |
| 21 |
28476032 | Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines. | 2017 Jun 20 |
3 |
| 22 |
29029490 | 7-ketocholesterol and 27-hydroxycholesterol decreased doxorubicin sensitivity in breast cancer cells: estrogenic activity and mTOR pathway. | 2017 Sep 12 |
2 |
| 23 |
26545405 | Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. | 2016 Jan |
1 |
| 24 |
26607462 | Furanodiene enhances the anti-cancer effects of doxorubicin on ERα-negative breast cancer cells in vitro. | 2016 Mar 5 |
3 |
| 25 |
27510756 | The protective role of p72 in doxorubicin‑induced cardiomyocytes injury in vitro. | 2016 Oct |
3 |
| 26 |
27657062 | Anthocyanin Attenuates Doxorubicin-Induced Cardiomyotoxicity via Estrogen Receptor-α/β and Stabilizes HSF1 to Inhibit the IGF-IIR Apoptotic Pathway. | 2016 Sep 21 |
1 |
| 27 |
25947916 | Luteolin attenuates doxorubicin-induced cytotoxicity to MCF-7 human breast cancer cells. | 2015 |
2 |
| 28 |
26279450 | N1-Guanyl-1,7-Diaminoheptane Sensitizes Estrogen Receptor Negative Breast Cancer Cells to Doxorubicin by Preventing Epithelial-Mesenchymal Transition through Inhibition of Eukaryotic Translation Initiation Factor 5A2 Activation. | 2015 |
4 |
| 29 |
24721327 | Tamoxifen guided liposomes for targeting encapsulated anticancer agent to estrogen receptor positive breast cancer cells: in vitro and in vivo evaluation. | 2014 May |
4 |
| 30 |
25213022 | Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers. | 2014 Sep 11 |
1 |
| 31 |
23218766 | High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer. | 2013 Apr |
1 |
| 32 |
22404783 | Design, synthesis, and initial biological evaluation of a steroidal anti-estrogen-doxorubicin bioconjugate for targeting estrogen receptor-positive breast cancer cells. | 2012 Apr 18 |
1 |
| 33 |
22442272 | Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression. | 2012 Jun |
2 |
| 34 |
22578285 | A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy. | 2012 May 11 |
1 |
| 35 |
22801351 | Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer. | 2012 Sep |
1 |
| 36 |
23133636 | Doxorubicin influences the expression of glucosylceramide synthase in invasive ductal breast cancer. | 2012 |
7 |
| 37 |
20809360 | Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts. | 2011 Jul |
1 |
| 38 |
21801281 | Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer. | 2011 Nov |
1 |
| 39 |
20370682 | A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy. | 2010 May |
5 |
| 40 |
20422012 | The coordinated p53 and estrogen receptor cis-regulation at an FLT1 promoter SNP is specific to genotoxic stress and estrogenic compound. | 2010 Apr 21 |
1 |
| 41 |
19270784 | Bisphenol A at low nanomolar doses confers chemoresistance in estrogen receptor-alpha-positive and -negative breast cancer cells. | 2009 Feb |
2 |
| 42 |
19949674 | Impact of grade, hormone receptor, and HER-2 status in women with breast cancer on response to specific chemotherapeutic agents by in vitro adenosine triphosphate-based chemotherapy response assay. | 2009 Dec |
5 |
| 43 |
18258979 | Development of the 21-gene assay and its application in clinical practice and clinical trials. | 2008 Feb 10 |
1 |
| 44 |
16900372 | Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells. | 2007 Mar |
1 |
| 45 |
17538978 | Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. | 2007 Jul 15 |
2 |
| 46 |
16609087 | Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. | 2006 Apr 12 |
2 |
| 47 |
15588086 | Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells. | 2004 Dec 16 |
6 |
| 48 |
12703992 | [Status of estrogen receptor affects the drug sensitivity of drug-resistant MCF-7/Adr human breast cancer cells to droloxifene and Adriamycin]. | 2003 Apr |
2 |
| 49 |
12846414 | Inositol hexaphosphate (IP6) enhances the anti-proliferative effects of adriamycin and tamoxifen in breast cancer. | 2003 Jun |
1 |
| 50 |
12174911 | Differential modulation by estradiol of P-glycoprotein drug resistance protein expression in cultured MCF7 and T47D breast cancer cells. | 2002 Jul-Aug |
1 |